These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2475521)

  • 61. Production of B-cell growth factor interleukin 2 and gamma interferon by peripheral blood lymphocytes from patients with chronic lymphocytic leukemia of B-cell type.
    Rossi JF; Commes T; Grenier J; Jourdan M; Chichehian B; Klein B
    Am J Hematol; 1988 Dec; 29(4):183-8. PubMed ID: 3142255
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL).
    Zocchi MR; Poggi A; Heltai S; Villa A; Inverardi L; Vicari A; Sabbadini MG; Ferrarini M
    Clin Exp Immunol; 1990 Oct; 82(1):108-13. PubMed ID: 1976463
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
    Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
    Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
    Wang P; Vánky F; Klein E
    Int J Cancer; 1992 Jul; 51(6):962-7. PubMed ID: 1386348
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
    Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
    Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New perspectives on the approach to chronic lymphocytic leukemia.
    Goodman MG; Spinosa JC; Saven A; Piro LD; Wormsley S
    Leuk Lymphoma; 1996 Jun; 22(1-2):1-10. PubMed ID: 8724523
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Renal allograft rejection: protection of renal epithelium from natural killer cells by cytokine-induced up-regulation of class I major histocompatibility antigens.
    Lin Y; Proud G; Taylor RM; Kirby JA
    Immunology; 1993 Jun; 79(2):290-7. PubMed ID: 8344707
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
    Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
    Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
    Patel SS; Thiele DL; Lipsky PE
    J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unmasking of cryptic natural killer (NK) cell recognition sites on chronic lymphocytic leukemia lymphocytes.
    Spitz DL; Zucker-Franklin D; Nabi ZF
    Am J Hematol; 1988 Jul; 28(3):155-61. PubMed ID: 3136646
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Generation of natural killer-like activity in mixed lymphocyte-tumor cell cultures. II. Correlation between expression of HLA-DR antigens on the activated T cells and their cytotoxic capability.
    Santoli D; Francis MK; Matera L
    Nat Immun Cell Growth Regul; 1985; 4(2):103-12. PubMed ID: 3160933
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.
    Hersey P; MacDonald M; Schibeci S; Burns C
    Cancer Immunol Immunother; 1986; 22(1):15-23. PubMed ID: 2423240
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stimulation by CLL cells in mixed lymphocyte culture (MLC).
    Jones EH; Hockley AB; Lawler SD
    Br J Cancer; 1981 Nov; 44(5):675-81. PubMed ID: 6172142
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.
    Calvo T; Reina-Ortiz C; Giraldos D; Gascón M; Woods D; Asenjo J; Marco-Brualla J; Azaceta G; Izquierdo I; Palomera L; Sánchez-Martínez D; Marzo I; Naval J; Vilches C; Villalba M; Anel A
    Sci Rep; 2020 Nov; 10(1):19398. PubMed ID: 33173077
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human interleukin 4 regulates the phenotype of lymphocytes generated during mixed lymphocyte culture and inhibits the IL-2-induced development of LAK function in normal and leukaemic cells.
    Jin BQ; Lopez AF; Gillis S; Juttner CA; Vadas MA; Burns GF
    Leuk Res; 1989; 13(4):297-305. PubMed ID: 2523990
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.
    Vánky F; Wang P; Patarroyo M; Klein E
    Cancer Immunol Immunother; 1990; 31(1):19-27. PubMed ID: 1968361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.